References
- Doherty GA, Cheifetz AS. Management of acute severe ulcerative colitis. Expert Rev. Gastroenterol. Hepatol.3(4), 395–405 (2009).
- Mackey AC, Green L, Liang LC et al. Hepatosplenic T cell lymphoma associated with infliximab use in young patients treated for inflammatory bowel disease. J. Pediatr. Gastroenterol. Nutr.44(2), 265–267 (2007).
- Lichtenstein GR, Cohen RD, Feagan BG et al. Serious infections and mortality in association with therapies for Crohn’s disease: TREAT registry. Clin. Gastroenterol. Hepatol.4, 621–630 (2006).
- Siegel CA, Marden SM, Persing SM et al. Risk of lymphoma associated with anti-TNF agents for the treatment of Crohn’s disease: a meta-analysis. Gastroenterology134(4 Suppl. 1), A144 (2008).
- Zeddy JG, Loftus EV. Safety of infliximab and other biologic agents in the inflammatory bowel diseases. Gastroenterol. Clin. N. Am.35, 837–855 (2006).
- Rutgeerts P, Sandborn WJ, Feagan BG et al. Infliximab for induction and maintenance therapy for ulcerative colitis. N. Engl. J. Med.353(23), 2462–2476 (2005).
- Toruner M, Loftus EV Jr, Harmsen WS et al. Risk factors for opportunistic infections in patients with inflammatory bowel disease. Gastroenterology134(4), 929–936 (2008).
- Cohen RD, Brodsky AL, Hanauer SB. A comparison of the quality of life in patients with severe ulcerative colitis after total colectomy versus medical treatment with intravenous cyclosporin. Inflam. Bowel Dis.5(1), 1–10 (1999).
- Lichtenstein GR, Cohen R, Yamashita B, Diamond RH. Quality of life after proctocolectomy with ileoanal anastomosis for patients with ulcerative colitis. J. Clin. Gastroenterol.40(8), 669–677 (2006).
- Roberts SE, Williams JG, Yeates D et al. Mortality in patients with and without colectomy admitted to hospital for ulcerative colitis and Crohn’s disease: record linkage studies. BMJ335(7628), 1033 (2007).